Swedish Orphan Biovitrum AB (Swedish Orphan Biovitrum AB) Days Sales Outstanding : 78.92 (As of Mar. 2024)

View and export this data going back to 2023. Start your Free Trial

What is Swedish Orphan Biovitrum AB Days Sales Outstanding?

Swedish Orphan Biovitrum AB's average Accounts Receivable for the three months ended in Mar. 2024 was $520 Mil. Swedish Orphan Biovitrum AB's Revenue for the three months ended in Mar. 2024 was $601 Mil. Hence, Swedish Orphan Biovitrum AB's Days Sales Outstanding for the three months ended in Mar. 2024 was 78.92.

The historical rank and industry rank for Swedish Orphan Biovitrum AB's Days Sales Outstanding or its related term are showing as below:

SWOBY' s Days Sales Outstanding Range Over the Past 10 Years
Min: 42.78 Med: 65.9 Max: 89.58
Current: 74.49

During the past 13 years, Swedish Orphan Biovitrum AB's highest Days Sales Outstanding was 89.58. The lowest was 42.78. And the median was 65.90.

SWOBY's Days Sales Outstanding is ranked worse than
52.15% of 1001 companies
in the Drug Manufacturers industry
Industry Median: 72.57 vs SWOBY: 74.49

Swedish Orphan Biovitrum AB's Days Sales Outstanding declined from Mar. 2023 (82.91) to Mar. 2024 (78.92).

Swedish Orphan Biovitrum AB Days Sales Outstanding Historical Data

The historical data trend for Swedish Orphan Biovitrum AB's Days Sales Outstanding can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Swedish Orphan Biovitrum AB Days Sales Outstanding Chart

Swedish Orphan Biovitrum AB Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Days Sales Outstanding

Get a 7-Day Free Trial

70.12

84.52

88.38

89.10

85.43

Swedish Orphan Biovitrum AB Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Days Sales Outstanding	Get a 7-Day Free Trial															82.91	82.02	77.45	60.54	78.92

Competitive Comparison of Swedish Orphan Biovitrum AB's Days Sales Outstanding

For the Drug Manufacturers - Specialty & Generic subindustry, Swedish Orphan Biovitrum AB's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Swedish Orphan Biovitrum AB's Days Sales Outstanding Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Swedish Orphan Biovitrum AB's Days Sales Outstanding distribution charts can be found below:

* The bar in red indicates where Swedish Orphan Biovitrum AB's Days Sales Outstanding falls into.

Swedish Orphan Biovitrum AB Days Sales Outstanding Calculation

Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Accounts Receivable can be measured by Days Sales Outstanding.

Swedish Orphan Biovitrum AB's Days Sales Outstanding for the fiscal year that ended in Dec. 2023 is calculated as

	Days Sales Outstanding (A: Dec. 2023 )
=	Average Accounts Receivable					/	Revenue	*	Days in Period
=	( (Accounts Receivable (A: Dec. 2022 )	+	Accounts Receivable (A: Dec. 2023 ))	/	count )	/	Revenue (A: Dec. 2023 )	*	Days in Period
=	( (505.685	+	503.919)	/	2 )	/	2156.742	*	365
=	504.802					/	2156.742	*	365
=	85.43

Swedish Orphan Biovitrum AB's Days Sales Outstanding for the quarter that ended in Mar. 2024 is calculated as:

	Days Sales Outstanding (Q: Mar. 2024 )
=	Average Accounts Receivable					/	Revenue	*	Days in Period
=	( (Accounts Receivable (A: Dec. 2023 )	+	Accounts Receivable (A: Mar. 2024 ))	/	count )	/	Revenue (A: Mar. 2024 )	*	Days in Period
=	( (503.919	+	535.476)	/	2 )	/	600.886	*	365 / 4
=	519.6975					/	600.886	*	365 / 4
=	78.92

Swedish Orphan Biovitrum AB (OTCPK:SWOBY) Days Sales Outstanding Explanation

For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.

Swedish Orphan Biovitrum AB Days Sales Outstanding Related Terms

Thank you for viewing the detailed overview of Swedish Orphan Biovitrum AB's Days Sales Outstanding provided by GuruFocus.com. Please click on the following links to see related term pages.

Swedish Orphan Biovitrum AB (Swedish Orphan Biovitrum AB) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Swedish Orphan Biovitrum AB (OTCPK:SWOBY) » Definitions » Days Sales Outstanding

Comparable Companies

Traded in Other Exchanges

BIOVF:USA SOBI:Sweden SOBIs:UK 0MTD:UK B6E:Germany

Address

Tomtebodavagen 23 A, Solna, Stockholm, SWE, SE-112 76

Website

https://www.sobi.com

Swedish Orphan Biovitrum, or Sobi, focuses on rare diseases, primarily in hematology and immunology. Biovitrum started with experience in studying recombinant proteins such as hemophilia factors, and partnered with Syntonix (now part of Sanofi) on long-acting hemophilia factor replacement programs in 2006. Biovitrum acquired Orfadin and a partnered product business with the acquisition of Swedish Orphan. Sobi launched hemophilia products Alprolix and Eloctate in Europe in 2016. Sobi has since been building its immunology pipeline (rare disease drug Gamifant, U.S. rights to RSV antibodies Synagis and Beyfortus, gout drug SEL-212, complement drug Aspaveli) and hematology pipeline outside of hemophilia (thrombocytopenia drug Doptelet, blood cancer drug Zynlonta, myelofibrosis drug Vonjo).